On skin cancer awareness month this May, our teledermoscopy services have become available in the first pharmacy in Jersey. We are proud to partner with Reids Pharmacy to enable the ScreenCancer teledermoscopy service, to streamline and fast-track skin cancer diagnosis in new communities, however remote.
Skin cancer is the most prevalent cancer in the world, and melanoma is the most fatal of skin cancer types, with over 300,000 patients diagnosed and over50,000 deaths in 2020. Early detection of skin cancer is vital. In fact, localized skin cancer lesions can be easily removed, whereas once in metastatic phase, skin cancer is unfortunately fatal for most patients.
DeepX Health’s offers teledermoscopy services in over 280 community pharmacies, primary care practices and aesthetic clinics in UK and Europe. Our service allows accessible and prompt scanning of suspicious lesions and early detection of skin cancer. Our teledermoscopy service is delivered through DeepX Health’s DermoSight dermatoscopic tool. Our network of dermatology specialists reviews the images remotely and provide an expert and confidential diagnosis.
“We are proud to be the first pharmacy offering such a vital and affordable service to our community in Jersey. Scanning suspect lesions in the pharmacy spares the patients unnecessary visits and long waits to see a dermatologist and can help fast-track treatment for those lesions that require further attention,” said Nicki Reid, Director at the Jersey pharmacy chain.
DeepX Diagnostics Inc.'s DermoSight Receives FDA Clearance for Teledermatology Screening of Suspect Skin Cancer Lesions
Read morePharmacy Screening Demonstrates Great Efficiency and Potential for Cost Reductions
Read moreDeepX Health to Present at the 8th World Congress of Teledermatology, Imaging and Artificial Intelligence for Skin Diseases
Read moreDeepX Health to participate at the 7th Annual Dermatology Summit in San Francisco
Read more